study on the maintenance strategy of biological agents for elderly rheumatoid arthritis based on treat to target

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075871

Enrollment

Unknown

Registered

2023-09-18

Start date

2023-09-25

Completion date

Unknown

Last updated

2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

clinical remission:Follow up every 12 weeks to evaluate the Treatment to Target. If not reach the target,first increase the TNFi dose to the standard dose, and then adjust the csDMARDs (including meth

If reach the target ,the TNFi was reduced and maintained until the maintenance dose was achieved. The order of reduction was YSP/ETA 50mg QW, 25mg QW, 25mg Q2W (maintenance dose), ADA 40mg Q2W, Q3W, Q

low disease activity group:Follow up every 12 weeks to evaluate the Treatment to Target. If not reach the target,first increase the TNFi dose to the standard dose, and then adjust the csDMARDs (includ

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: ?Age = 60 years old; ?Meets the 2010 ACR/Eular classification diagnostic criteria for RA; ?After at least one type of csDMARDs combined with TNFi treatment for = 12 weeks, and the improvement in SDAI= 50% .

Exclusion criteria

Exclusion criteria: Individuals who have participated in clinical trials within the past 6 months. Application of oral corticosteroids during the screening period,or have used glucocorticoids for intra-articular or intramuscular or intravenous injections within the past month. Individuals with a history of active gastric ulcers. Individuals with obvious blood system diseases and abnormal laboratory tests(WBC<4×10^9 /L or PLT<100×10^9/L). ALT?2×ULN,AST?2×ULN,GFR?40ml/min. Individuals with a history of acute or chronic infection (including but not limited to viral hepatitis, herpes zoster virus, tuberculosis, etc.). Individuals with a history of malignant tumors, compensatory dysfunction of heart function, or severe hypertension, epilepsy, and other neurological disorders. Individuals with a history of alcoholism within 2 years.

Design outcomes

Primary

Measure	Time frame
Disease activity index;Adverse reactions;medical expense;	—

Countries

China

Contacts

Public ContactChen Yingjuan

Beijing Hospital

cyjnew@aliyun.com+86 136 5132 4699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026